Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Medical System HoldingsCHSYF +0.11%87 ROC (Joel Greenblatt) % is 80.98% as of Dec. 2025, which is 52% below its 10-year median of 169.85. GuruFocus rates CHSYF with a GF Score™ of 87/100 and a GF Value™ of $1.30 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 982 Drug Manufacturers companies, China Medical System Holdings ranks better than 92.77% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. China Medical System Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 80.98%.
The historical rank and industry rank for China Medical System Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:
CHSYF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 94.27 Med: 169.85 Max: 245.63
Current: 94.27
During the past 13 years, China Medical System Holdings's highest ROC (Joel Greenblatt) % was 245.63%. The lowest was 94.27%. And the median was 169.85%.
CHSYF's ROC (Joel Greenblatt) % is ranked better than 92.77% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.405
vs CHSYF: 94.27
China Medical System Holdings (OTCPK:CHSYF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Medical System Holdings ROC (Joel Greenblatt) % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Medical System Holdings ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where China Medical System Holdings's ROC (Joel Greenblatt) % falls into.
China Medical System Holdings ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 80.98% mean?
China Medical System Holdings (CHSYF) has a ROC (Joel Greenblatt) % of 80.98% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on China Medical System Holdings and its competitors. This is 52% below median its historical median of 169.85. Over the past decade, China Medical System Holdings' ROC (Joel Greenblatt) % has ranged from 94.27 to 245.63. According to the industry distribution chart, China Medical System Holdings ranks #71 out of 982 companies in the Drug Manufacturers industry, placing it in the top 7.2%.
Is China Medical System Holdings' ROC (Joel Greenblatt) % too high?
China Medical System Holdings' current ROC (Joel Greenblatt) % of 80.98% is 52% below median its 10-year median of 169.85. Over the past 10 years, this metric has ranged from a low of 94.27 to a high of 245.63. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.41. China Medical System Holdings' value of 80.98% is 610% above this industry median. Based on the distribution chart, China Medical System Holdings ranks #71 out of 982 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Medical System Holdings has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Medical System Holdings' ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Medical System Holdings ranks #71 out of 982 companies for ROC (Joel Greenblatt) %. This places China Medical System Holdings in the top 7% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.41. China Medical System Holdings' value of 80.98% is 610% above this benchmark. Historically, China Medical System Holdings' own ROC (Joel Greenblatt) % has ranged from 94.27 to 245.63 over the past decade. While the company's 10-year median is 169.85 vs. the industry median of 11.41, China Medical System Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.41, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Medical System Holdings's current ROC (Joel Greenblatt) % of 80.98% is 610% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on China Medical System Holdings and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Medical System Holdings's current ROC (Joel Greenblatt) % is 80.98%, which is 52% below median its own 10-year median of 169.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Medical System Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Medical System Holdings (CHSYF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.30, compared to a current price of $1.57 — trading 20.8% above its estimated fair value. The current ROC (Joel Greenblatt) % is 80.98%, which is 52% below median its 10-year median of 169.85 and 610% above the Drug Manufacturers industry median of 11.41. China Medical System Holdings' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For China Medical System Holdings (CHSYF), the current ROC (Joel Greenblatt) % is 80.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Medical System Holdings (CHSYF) Overvalued in 2026?
Based on GuruFocus' analysis, China Medical System Holdings stock appears to be overvalued.
The current stock price of $1.57 is trading 20.8% above its estimated GF Value™ of $1.30.
GuruFocus considers China Medical System Holdings to be Modestly Overvalued.
Key valuation signals for CHSYF:
ROC (Joel Greenblatt) %: 80.98% (52% below median its 10-year median of 169.85)
GF Value™: $1.30 vs. price of $1.57 (20.8% above fair value)
Industry Position: 610% above the Drug Manufacturers median (#71 of 982)
No single metric tells the full story. See the CHSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Medical System Holdings Ltd is a holding company. Along with its subsidiaries, it is engaged in the research and development, production, promotion and sale of medicines. The company's reportable segments are: (i) Integrated pharmaceuticals portfolio and (ii) Skin diseases related business. The majority of the company's revenue, which consists of pharmaceutical products sales, is derived from the integrated pharmaceuticals portfolio segment.
87GF Score
Get the complete analysis for CHSYF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHSYF has been successfully added to your 
